Comparative Pharmacology
Head-to-head clinical analysis: CARVEDILOL PHOSPHATE versus COREG CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARVEDILOL PHOSPHATE versus COREG CR.
CARVEDILOL PHOSPHATE vs COREG CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive beta-blocker with alpha1-blocking activity; decreases cardiac output, reduces peripheral vascular resistance.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
6.25 mg orally twice daily, titrated up to a maximum of 25 mg twice daily for heart failure; 12.5 mg orally once daily for hypertension, titrated to 25-50 mg daily.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
None Documented
None Documented
7-10 hours (terminal elimination half-life); clinical context: supports twice-daily dosing for sustained beta-blockade.
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
Primarily hepatic metabolism (CYP2D6 and CYP2C9) followed by biliary excretion into feces; ~60% fecal elimination as metabolites, ~16% renal elimination of unchanged drug plus metabolites.
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Category C
Category C
Alpha/Beta-Blocker
Beta-Blocker